Zevra Therapeutics Inc(ZVRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
AI-drawn chart patterns are for reference only.
Full metrics table
| Index | RUT | P/E | 9.97 | EPS (ttm) | 1.2 | Insider Own | 1.46% | Shs Outstand | 59.4M | Perf Week | 16.18% |
| Market Cap | 0.71B | Forward P/E | 12.82 | EPS next Y | -26.26% | Insider Trans | -11.36% | Shs Float | 58.6M | Perf Month | 5.3% |
| Enterprise Value | 0.51B | PEG | 5.99 | EPS next Q | 0.19 | Inst Own | 79.31% | Short Float | 11.18% | Perf Quarter | 4.2% |
| Income | 0.07B | P/S | 4.8 | EPS this Y | -6.58% | Inst Trans | 6.66% | Short Ratio | 7.26 | Perf Half Y | 7.87% |
| Sales | 0.15B | P/B | 2.97 | EPS next 5Y | 2.14% | ROA | 25.69% | Short Interest | 6.56M | Perf YTD | 33.04% |
| Book/sh | 4.02 | P/C | 3.63 | EPS past 3/5Y | - | ROE | 40.29% | 52W High | -20.72% ($15.03) | Perf Year | 30.99% |
| Cash/sh | 3.29 | P/FCF | 18.53 | Sales past 3/5Y | 118.82% 51.62% | ROIC | 31.3% | 52W Low | 48.81% ($8.01) | Perf 3Y | 187.23% |
| Dividend Est. | - | EV/EBITDA | 10.76 | EPS Y/Y TTM | 103.22% | Gross Margin | 94.52% | Volatility(W/M) | 7.13% 5.2% | Perf 5Y | 30.99% |
| Dividend TTM | - | EV/Sales | 3.49 | Sales Y/Y TTM | 75.1% | Oper. Margin | 31.47% | ATR (14) | 0.57 | Perf 10Y | -81.83% |
| Dividend Ex-Date | - | Quick Ratio | 5.38 | EPS Q/Q | 2767.01% | Profit Margin | 50.73% | RSI (14) | 61.44 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.46 | Sales Q/Q | 44.86% | SMA20 | 13.62% ($10.49) | Beta | 0.97 | Target Price | $25.25 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/11/3 | SMA50 | 7.56% ($11.08) | Rel Volume | 1.18 | Prev Close | $12.14 |
| Employees | 61 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 64.97% 1.82% | SMA200 | 10.17% ($10.82) | Avg Volume(3M) | 0.90M | Price | $11.92 |
| IPO | 2015/4/16 | Option/Short | Yes/Yes | Trades | 8281 | Volume | 1,063,540 | Change | -1.81% |
🧬 Zevra Therapeutics (ZVRA) is a commercial-stage biotech company focused on therapies for rare diseases. Its lead product, MIPLYFFA (arimoclomol), is approved in the US for the treatment of Niemann-Pick disease type C, and the company is expanding its rare disease portfolio through acquisitions that added OLPRUVA and the candidate celiprolol. What sets it apart is its parallel pursuit of product launches and pipeline expansion, targeting patient populations with significant unmet medical needs.
Over the past 1 year, roughly in the middle
21% below its 1-year high.
Traded about as much as usual. That is 118% of its average volume.
ZVRA makes money exceptionally well
Of every $100 in sales, $31.47 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -6.6% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,076. Peers typically go for $1,076. Compared with its own 1-year average, it is 13% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 5 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +31.0%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 79.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #187 of 597 in the industry
Based on market cap of $709M.
CGEM#185 Cullinan Therapeutics Inc $723M PER - 
CADL#186 Candel Therapeutics Inc $715M PER - ZVRA#187 Zevra Therapeutics Inc $709M PER 10.0 
PRME#188 Prime Medicine Inc $707M PER - 
IAM#189 Iambic Therapeutics Inc $701M PER - 
FAQ
What kind of company is ZVRA?
ZVRA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ZVRA?
The market cap of ZVRA is approximately $709M, ranking 2,845 within its sector.
What is the P/E ratio of ZVRA?
ZVRA has a P/E ratio of approximately 10.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ZVRA?
ZVRA has recorded a 52-week high of $15.03 and a low of $8.01.
